[{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"4811680a-497e-488d-8abd-34a9b22c5b1c","acronym":"TeliMET NSCLC-01","url":"https://clinicaltrials.gov/study/NCT04928846","created_at":"2021-06-16T18:52:53.966Z","updated_at":"2025-02-25T15:35:07.629Z","phase":"Phase 3","brief_title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04928846 - TeliMET NSCLC-01","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-10"},{"id":"13166d68-2e61-4c72-92f1-fac024df7835","acronym":"SAFFRON","url":"https://clinicaltrials.gov/study/NCT05261399","created_at":"2022-03-02T17:52:38.442Z","updated_at":"2024-07-02T16:34:59.035Z","phase":"Phase 3","brief_title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","source_id_and_acronym":"NCT05261399 - SAFFRON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/26/2025","primary_completion_date":" 06/26/2025","study_txt":" Completion: 12/17/2026","study_completion_date":" 12/17/2026","last_update_posted":"2024-06-04"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"a3747950-095a-48c6-aa37-bde9bcafea6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083857","created_at":"2023-10-16T16:13:46.888Z","updated_at":"2024-07-02T16:35:06.404Z","phase":"Phase 1/2","brief_title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06083857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-02"},{"id":"ba256708-bd68-4aa8-a289-341634b3901f","acronym":"SOUND","url":"https://clinicaltrials.gov/study/NCT05374603","created_at":"2022-05-16T13:53:43.301Z","updated_at":"2024-07-02T16:35:16.700Z","phase":"Phase 2","brief_title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05374603 - SOUND","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Orpathys (savolitinib)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"44f9e1b3-6856-412b-91b0-43acf5d977c5","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT02034981","created_at":"2021-01-17T17:58:03.438Z","updated_at":"2024-07-02T16:35:17.368Z","phase":"Phase 2","brief_title":"Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1","source_id_and_acronym":"NCT02034981 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" ALK • MET • ROS1","pipe":" | ","alterations":" ALK positive • MET overexpression • ALK translocation","tags":["ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET overexpression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 246","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-02-28"},{"id":"d50a34e4-2472-47b7-9a2f-79140a198661","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052971","created_at":"2022-05-05T23:54:22.816Z","updated_at":"2024-07-02T16:35:18.863Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation","source_id_and_acronym":"NCT04052971","lead_sponsor":"Abion Inc","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vabametkib (ABN401)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-19"},{"id":"f2a04229-a963-4571-967a-2d4ee1ac84df","acronym":"FLOWERS","url":"https://clinicaltrials.gov/study/NCT05163249","created_at":"2021-12-20T15:53:31.602Z","updated_at":"2024-07-02T16:35:19.919Z","phase":"Phase 2","brief_title":"Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC","source_id_and_acronym":"NCT05163249 - FLOWERS","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-09"},{"id":"30039935-dcb8-4bf7-a489-908bf7235f71","acronym":"LUMINOSITY","url":"https://clinicaltrials.gov/study/NCT03539536","created_at":"2021-01-18T17:26:22.732Z","updated_at":"2024-07-02T16:35:22.832Z","phase":"Phase 2","brief_title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03539536 - LUMINOSITY","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • MET overexpression • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-01-19"},{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"},{"id":"4517ce65-ebe5-48ef-b3a0-5e1b03bf3e96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093503","created_at":"2023-10-23T20:13:56.005Z","updated_at":"2024-07-02T16:35:32.453Z","phase":"Phase 3","brief_title":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","source_id_and_acronym":"NCT06093503","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 04/11/2028","primary_completion_date":" 04/11/2028","study_txt":" Completion: 04/11/2028","study_completion_date":" 04/11/2028","last_update_posted":"2023-10-20"},{"id":"2d001bd0-721f-4093-a13e-a279286606b0","acronym":"FirstMET","url":"https://clinicaltrials.gov/study/NCT05777278","created_at":"2023-03-21T14:02:59.639Z","updated_at":"2024-07-02T16:35:34.134Z","phase":"Phase 1/2","brief_title":"Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression","source_id_and_acronym":"NCT05777278 - FirstMET","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" MET overexpression","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2023-10-10"},{"id":"6575bade-72bb-495f-8e06-eb39a449767d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639508","created_at":"2021-01-17T17:26:36.480Z","updated_at":"2024-07-02T16:35:44.723Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","source_id_and_acronym":"NCT01639508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" RET • ROS1 • KIF5B • AXL • NTRK","pipe":" | ","alterations":" RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion","tags":["RET • ROS1 • KIF5B • AXL • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-26"},{"id":"1ee70366-b7a8-4f46-abc0-90483806c589","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744652","created_at":"2021-01-18T07:38:47.984Z","updated_at":"2024-07-02T16:35:46.306Z","phase":"Phase 1","brief_title":"Dasatinib and Crizotinib in Advanced Cancer","source_id_and_acronym":"NCT01744652","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • ALK • MET • CDKN2A • DDR2 • CTGF","pipe":" | ","alterations":" BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification","tags":["BRAF • ALK • MET • CDKN2A • DDR2 • CTGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-06-07"},{"id":"34d5b5f4-1e3a-4200-8350-19e639ccf1ab","acronym":"SANOVO","url":"https://clinicaltrials.gov/study/NCT05009836","created_at":"2021-08-18T15:53:38.104Z","updated_at":"2024-07-02T16:35:51.870Z","phase":"Phase 3","brief_title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05009836 - SANOVO","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-03-30"},{"id":"049acb0a-e716-4715-af42-f30f1499423c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05750290","created_at":"2023-03-01T15:02:17.647Z","updated_at":"2024-07-02T16:35:54.451Z","phase":"Phase 2","brief_title":"CKD-702 Plus Irinotecan in Gastric Cancer","source_id_and_acronym":"NCT05750290","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression • MET overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • CKD-702"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-01"},{"id":"952c0c39-ad39-476d-90fc-c92d7fa765f6","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT01982955","created_at":"2021-01-17T17:35:00.093Z","updated_at":"2025-02-25T14:49:47.416Z","phase":"Phase 1/2","brief_title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","source_id_and_acronym":"NCT01982955 - INSIGHT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gefitinib • pemetrexed • Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 12/23/2013","start_date":" 12/23/2013","primary_txt":" Primary completion: 12/12/2017","primary_completion_date":" 12/12/2017","study_txt":" Completion: 10/14/2021","study_completion_date":" 10/14/2021","last_update_posted":"2022-11-08"},{"id":"726018f8-a8bb-47b9-b507-183575dc2a24","acronym":"MErCuRIC1","url":"https://clinicaltrials.gov/study/NCT02510001","created_at":"2021-01-18T12:07:19.285Z","updated_at":"2025-02-25T15:33:28.804Z","phase":"Phase 1","brief_title":"MEK and MET Inhibition in Colorectal Cancer","source_id_and_acronym":"NCT02510001 - MErCuRIC1","lead_sponsor":"University of Oxford","biomarkers":" KRAS • MET • NRAS","pipe":" | ","alterations":" MET amplification • MET overexpression • RAS mutation • MET expression","tags":["KRAS • MET • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RAS mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Mektovi (binimetinib) • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2021-07-13"},{"id":"cb3edfcf-83c1-43e0-b3bf-9c781f80edfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169178","created_at":"2021-01-18T20:20:27.015Z","updated_at":"2024-07-02T16:36:45.411Z","phase":"Phase 1","brief_title":"Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status","source_id_and_acronym":"NCT04169178","lead_sponsor":"Henlix, Inc","biomarkers":" KRAS • MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression • MET mutation","tags":["KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX55"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-05-01"},{"id":"3221b2ed-59d5-42f8-9362-f16e8b9e7f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03466268","created_at":"2021-01-17T17:53:18.793Z","updated_at":"2024-07-02T16:36:48.917Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety and Anti-tumor Activity of SCC244","source_id_and_acronym":"NCT03466268","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET exon 14 mutation • MET overexpression • ALK mutation • MET mutation • ROS1 wild-type","tags":["KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET exon 14 mutation • MET overexpression • ALK mutation • MET mutation • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Haiyitan (gumarontinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 113","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2020-03-11"},{"id":"faffdd28-d29f-488c-a19b-3cd50c82dd51","acronym":"","url":"https://clinicaltrials.gov/study/NCT03147976","created_at":"2021-01-27T18:55:48.199Z","updated_at":"2024-07-02T16:36:56.317Z","phase":"Phase 2","brief_title":"QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03147976","lead_sponsor":"NantPharma, LLC","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET overexpression • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 337"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 08/23/2019","primary_completion_date":" 08/23/2019","study_txt":" Completion: 08/23/2019","study_completion_date":" 08/23/2019","last_update_posted":"2019-08-28"},{"id":"f0387d12-fa4e-40e1-addf-226e0d4ad5ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00900328","created_at":"2021-01-18T03:28:03.237Z","updated_at":"2024-07-02T16:37:19.075Z","phase":"","brief_title":"Study of Tumor Samples From Patients With Lung Cancer","source_id_and_acronym":"NCT00900328","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" EGFR • KRAS • ALK • TP53 • MET • CBL","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression","tags":["EGFR • KRAS • ALK • TP53 • MET • CBL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression"],"overall_status":"Completed","enrollment":" Enrollment 280","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2017-08-08"}]